Feature Papers on Respiratory Virus Infections

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Public Health Microbiology".

Deadline for manuscript submissions: 31 January 2026 | Viewed by 542

Special Issue Editors


E-Mail Website
Guest Editor
Department of Virology III, National Institute of Infectious Diseases, Musashimurayama-shi, Tokyo 208-0011, Japan
Interests: parainfluenza virus

Special Issue Information

Dear Colleagues,

Respiratory viruses remain a significant threat to global public health, causing substantial morbidity and mortality worldwide. During transmission and spread, these viruses accumulate mutations in their nucleotide sequences, leading to amino acid substitutions that can alter pathogenicity and drive adaptation to hosts such as humans.

With the widespread adoption of next-generation sequencing (NGS), a large number of full-length viral genome sequences have been deposited in international databases such as GISAID and NCBI GenBank. Concurrently, advances in bioinformatics have enabled the efficient analysis of these vast datasets, facilitating deeper insights into the genetic diversity and evolutionary dynamics of respiratory viruses. As a result, this research area has become increasingly important for informing vaccine and antiviral drug development.

This Special Issue aims to comprehensively cover recent advances and emerging perspectives on a wide range of respiratory viruses, including influenza virus, respiratory syncytial virus (RSV), human parainfluenza virus (HPIV), rhinovirus, human metapneumovirus (HMPV), and coronaviruses. We welcome submissions addressing diverse areas such as molecular epidemiology, viral evolution, transmission dynamics, host–pathogen interactions, and strategies for vaccine and antiviral development.

Prof. Dr. Hirokazu Kimura
Dr. Fuminori Mizukoshi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • respiratory viruses
  • next-generation sequencing
  • molecular epidemiology
  • viral evolution
  • host–pathogen interactions
  • transmission dynamics
  • vaccine development
  • antiviral strategies
  • genomic surveillance
  • phylogenetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2600 KB  
Article
COVID-19 is Associated with a Lipid Storm that Worsens in Cases of Severe Pneumonia
by Amani Bouabdallah, Mohamed Kacem Ben-Fradj, Mohamed Bessem Hammami, Rim Abdelmalek, Haifa Sanhaji, Timothée Klopfenstein and Moncef Feki
Microorganisms 2025, 13(11), 2622; https://doi.org/10.3390/microorganisms13112622 - 19 Nov 2025
Viewed by 393
Abstract
Severe Coronavirus disease 2019 (COVID-19) is associated with abnormal innate and adaptive immune responses, as well as systemic alterations, including a shift in lipid network. A case–control study was conducted to describe the systemic lipidomic profile in COVID-19 according to disease severity. Selected [...] Read more.
Severe Coronavirus disease 2019 (COVID-19) is associated with abnormal innate and adaptive immune responses, as well as systemic alterations, including a shift in lipid network. A case–control study was conducted to describe the systemic lipidomic profile in COVID-19 according to disease severity. Selected polyunsaturated fatty acids (PUFAs), oxylipins, and endocannabinoids were analysed using a targeted liquid chromatography coupled to mass spectrometry in tandem method. Multivariate receiver operating characteristic curve-based model evaluation was performed to define a lipidomic signature for the disease. A total of 135 hospitalized COVID-19 patients, of whom 85 had severe form, and 134 healthy individuals were included. Patients exhibited increased levels of free PUFAs, proinflammatory and pro-resolving oxylipins, and endocannabinoids compared to controls. A combination of five lipid mediators, i.e., prostaglandin D2, prostaglandin E2, thromboxane B2, lipoxin B4, and 2-archidonylglycerol, discriminates patients from control individuals with excellent accuracy [AUC, 0.977 (0.950–0.995)]. The severe form is characterized by an imbalance between proinflammatory and pro-resolving oxylipins and increased endocannabinoids. COVID-19 is associated with a lipid storm that conditions disease severity. Targeting lipid mediators-related metabolic and signalling pathways could be an interesting therapeutic option in severe forms. Full article
(This article belongs to the Special Issue Feature Papers on Respiratory Virus Infections)
Show Figures

Figure 1

Back to TopTop